The rise of PSMA ligands for diagnosis and therapy of prostate cancer

Journal of Nuclear Medicine

Volumn 57, Issue , 2016, Pages 79S-89S

  Afshar Oromieh, Ali ^a,b   Babich, John W ^c   Kratochwil, Clemens ^a   Giesel, Frederik L ^a,b   Eisenhut, Michael ^b   Haberkorn, Uwe ^a,b   Kopka, Klaus ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Endoradiotherapy; PET CT; Prostate cancer; Prostate specific membrane antigen; PSMA

Indexed keywords

ACTINIUM 225; IODINE 131; LUTETIUM 177; MIP 1080 I 123; MIP 1095 I 131; MIP 1972 I 123; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN INHIBITOR; PSMA 11 GA 68; PSMA 617; TRACER; TROFOLASTAT TC 99M; UNCLASSIFIED DRUG; DIPEPTIDE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; PSMA-617; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS; TECHNETIUM 99M 1-(1-(2-(BIS(CARBOXYMETHYL)AMINO)-2-OXOETHYL)-1H-IMIDAZOL-2-YL)-2-((1-(2-(BIS(CARBOXYMETHYL)AMINO)-2-OXOETHYL)-1H-IMIDAZOL-2-YL)METHYL)-9,14-DIOXO-2,8,13,15-TETRAAZAOCTADECANE-7,12,16,18-TETRACARBOXYLIC ACID); TECHNETIUM COMPLEX;

ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDORADIOTHERAPY; HUMAN; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; IMAGE ENHANCEMENT; MALE; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

ANTIGENS, SURFACE; DIPEPTIDES; EVIDENCE-BASED MEDICINE; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMAGE ENHANCEMENT; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; ORGANOTECHNETIUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84991344059     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.170720     Document Type: Article

References (85)

1. Baek SE, Lee KH, Park YS, et al. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J Control Release. 2014; 196: 234-242.
2. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235: 623-628.
3. 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 976-983.
4. Maffioli L, Florimonte L, Costa DC, et al. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. Q J Nucl Med Mol Imaging 2015; 59: 420-438.
5. Santoni M, Scarpelli M, Mazzucchelli R, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014; 28: 555-563.
6. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996; 93: 749-753.
7. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM9 protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 1998; 58: 4787-4789.
8. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994; 54: 1807-1811.
9. Chang SS Overview of prostate-specific membrane antigen. Rev Urol. 2004; 6(suppl 10): S13-S18.
10. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334.
11. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-640.
12. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; 7: 927-935.
13. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997; 30: 232-242.
14. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001; 7: 27-37.
15. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998; 83: 739-747.
16. 18F]-FACBC) uptake. Am J Nucl Med Mol Imaging 2013; 3: 85-96.
17. 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol. 2004; 172: 133-136.
18. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radio-immunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate. 2004; 58: 145-155.
19. 177Lu? J Nucl Med. 2005; 46: 634-641.
20. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005; 23: 4591-4601.
21. Tagawa ST, Akhtar NH, Christos PJ, et al. Noninvasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a prognostic tool for metastatic castration-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol. 2013; 31(suppl): 11081.
22. 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014; 191: 1439-1445.
23. Morris MJ, Pandit-Taskar N, Tagawa ST, et al. Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591 [abstract]. J Clin Oncol. 2014; 32(suppl 4): 25.
24. De Gersem R, Jamar F. Nonspecific human immunoglobulin G for imaging infection and inflammation: what did we learn? Q J Nucl Med Mol Imaging 2010; 54: 617-628.
25. Jackson PF, Cole DC, Slusher BS, et al. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem. 1996; 39: 619-622.
26. Jackson PF, Slusher BS. Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr Med Chem. 2001; 8: 949-957.
27. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998; 286: 1020-1025.
28. Tiffany CW, Lapidus RG, Merion A, Calvin DC, Slusher BS. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate. 1999; 39: 28-35.
29. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001; 44: 298-301.
30. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 2002; 1: 96-101.
31. Kozikowski AP, Zhang J, Nan F, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004; 47: 1729-1738.
32. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009; 52: 347-357.
33. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013; 54: 380-387.
34. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013; 54: 1369-1376.
35. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014; 57: 2657-2669.
36. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013; 40: 819-823.
37. Nan F, Bzdega T, Pshenichkin S, et al. Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J Med Chem. 2000; 43: 772-774.
38. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005; 11: 4022-4028.
39. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69: 6932-6940.
40. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010; 53: 5333-5341.
41. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011; 52: 1087-1093.
42. 131I]MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa) [abstract]. Soc Nucl Med Annu Meet Abstr. 2012; 53: 170.
43. 131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa) [abstract]. J Nucl Med. 2011; 52(suppl 1): 361.
44. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014; 41: 1280-1292.
45. 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett. 2013; 23: 1557-1563.
46. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014; 55: 1791-1798.
47. 99mTc-MIP-1404 [abstract]. Soc Nucl Med Annu Meet Abstr. 2013; 54: 281.
48. 99mTc-trofolastat (MIP-1404) to identify prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection: an interim analysis [abstract]. Soc Nucl Med Annu Meet Abstr. 2014; 55: 15.
49. Dabasi G, Barra M, Tenke P, et al. Correlation of technetium Tc99m trofolastat chloride (MIP-1404) uptake using SPECT/CT with histopathology: a phase 2 study of prostate cancer (PCa) patients undergoing radical prostatectomy (RP) with extended lymph node dissection (ePLND). Eur J Nucl Med Mol Imaging 2014; 41(suppl): S236-S237.
50. 18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17: 7645-7653.
51. 18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015; 17: 565-574.
52. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23: 688-697.
53. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014; 7: 779-796.
54. 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39: 1085-1086.
55. 68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-495.
56. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20.
57. 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging 2016; 43: 1611-1620.
58. 68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 2015; 42: 210-214.
59. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015; 56: 1697-1705.
60. Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015; 56: 855-861.
61. 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015; 56: 1185-1190.
62. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
63. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015; 42: 1284-1294.
64. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015; 56: 668-674.
65. Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol. 2004; 19: 715-718.
66. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 2011; 108: 9578-9582.
67. Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol. 2012; 41: 2087-2092.
68. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. January 19, 2016 [Epub ahead of print].
69. 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016; 195: 1436-1443.
70. 68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1794-1800.
71. 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016; 43: 34-41.
72. 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014; 41: 887-897.
73. 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 70-83.
74. 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. January 18, 2016 [Epub ahead of print].
75. 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 1400-1406.
76. Benesová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015; 56: 914-920.
77. 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1976-1983.
78. 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 42-51.
79. 177Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016; 18: 437-445.
80. 177Lu]lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 987-988.
81. 177Lu-labeled PSMA-617. J Nucl Med. 2016; 57: 1170-1176.
82. 177Lu prostate-specific membrane antigen treatment in patient with metastatic prostate cancer. Clin Nucl Med. 2016; 41: 159-160.
83. 177Lu PSMA-617 therapy on bone marrow depression caused by metastatic prostate cancer. Clin Nucl Med. 2016; 41: 478-480.
84. 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7: 12477-12488.
85. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016; 57: 1006-1013.